SPYRE THERAPEUTICS, INC. Additional Paid in Capital, Common Stock
SPYRE THERAPEUTICS, INC. (SYRE) had Additional Paid in Capital, Common Stock of $2.19 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-04
- 2026-06-30: Additional Paid in Capital, Common Stock $2.19B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.71B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.69B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.36B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $2.19B 10-Q · filed 2026-08-04 |
| 2026-03-31 | $1.71B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $1.69B 10-Q · filed 2026-08-04 |
| 2025-09-30 | $1.36B 10-Q · filed 2025-11-04 |
| 2025-06-30 | $1.35B 10-Q · filed 2025-08-05 |
| 2025-03-31 | $1.34B 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.33B 10-K · filed 2026-02-19 |
| 2024-09-30 | $1.09B 10-Q/A · filed 2024-11-18 |
| 2024-06-30 | $1.07B 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $775.97M 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $763.19M 10-K · filed 2025-02-27 |
| 2023-09-30 | $455.96M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $453.74M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $477.70M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $475.97M 10-K/A · filed 2024-11-18 |
| 2022-09-30 | $474.54M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $472.94M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $428.05M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $425.76M 10-K · filed 2023-03-02 |
| 2021-09-30 | $423.44M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $420.06M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $417.95M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $415.82M 10-K · filed 2022-03-08 |
| 2020-09-30 | $389.54M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $387.48M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $256.78M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $255.14M 10-K · filed 2021-03-18 |
| 2019-09-30 | $253.33M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $251.59M 10-Q · filed 2019-08-06 |
| 2018-12-31 | $184.31M 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |